Meningococcal vaccine in travelers

  title={Meningococcal vaccine in travelers},
  author={Annelies Wilder-Smith},
  journal={Current Opinion in Infectious Diseases},
  • A. Wilder-Smith
  • Published 1 October 2007
  • Medicine
  • Current Opinion in Infectious Diseases
Purpose of review New vaccines to prevent meningococcal disease have been licensed in recent years. It is therefore timely to discuss current vaccine strategies pertinent to international travelers in relation to the changing epidemiology. Recent findings Serogroup W135 achieved epidemic status in Africa in 2002, and then largely disappeared over a short time period. The year 2006 saw a marked epidemic rise in meningitis attack rates across the meningitis belt in Africa. This rise was mainly… 
Meningococcal disease: risk for international travellers and vaccine strategies.
Protection of travellers against meningococcal disease: tetravalent conjugate vaccines offer new options *
With tourism expanding to traditionally less-often visited areas, there is a growing need to develop an awareness of the risks and the risk to acquire meningococcal disease.
Awareness of meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa.
It is concluded that improved education of travelers may improve vaccine uptake before travel to the meningitis belt in Africa and knowledge of certain key symptoms or signs were statistically associated with high vaccine uptake.
Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Implementation of MCC vaccination in Tuscany was effective in preventing meningococcal C disease, confirming the effectiveness of the vaccine.
Meningococcal vaccines: a neglected topic in travel medicine?
Conjugate meningococcal vaccines have significant advantages over polysaccharide vaccines, and should be the preferred option for travelers.
Vaccination of travelers: how far have we come and where are we going?
Vaccine recommendations are a prominent part of health preparations before international travel. We review progress made in the past decade regarding vaccines used primarily by persons traveling from
The epidemiology of meningococcal disease and the impact of vaccines
Development of vaccines for prevention of serogroups B disease in industrialized nations and serogroup A conjugate vaccines for Africa could lead to global control of meningococcal disease.


Meningococcal disease and travel.
Global Epidemiology of Meningococcal Disease and Vaccine Efficacy
  • A. Pollard
  • Medicine, Biology
    The Pediatric infectious disease journal
  • 2004
O Ongoing development of tetravalent A, C, Y, and W135 conjugate vaccines raises the hope that disease caused by these serogroups can be controlled in the near future.
Control of epidemic group A meningococcal meningitis in Nepal.
This experience demonstrates that it is possible, with appropriate surveillance efforts, to detect an evolving epidemic of meningococcal disease early in its course and to institute control measures in advance of the expected epidemic peak.
Meningococcal Disease in Travelers: Vaccination Recommendations.
For the usual traveler to endemic countries, the risk of infection abroad seems not to exceed the one at home, thus vaccination may be limited to high-risk groups, such as trekkers.
Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000
The increasing incidence of theserogroup X was not related to the decrease of serogroup A, but seemed cyclic, and evolved independently of the recurrence of both serogroups A and C.
A surveillance network for meningococcal disease in Europe.
A major decline in the incidence of invasive disease in those countries that have introduced routine vaccination against serogroup C infection is demonstrated and case fatality was found to vary with clonal complex, suggesting that genotype can be a marker for hypervirulence.
Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers.
An outbreak of disease due to Neisseria meningitidis serogroup W135 (W135) occurred among pilgrims returning from the annual Islamic pilgrimage to Saudi Arabia and in their contacts in 2000 and 2001 and the risk that an un vaccinated household contact who had acquired W135 carriage would develop invasive meningococcal disease was estimated to be 1 case per 70 acquisitions.
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.
For unknown reasons, serogroup W135 achieved epidemic status, primarily among young children, and then largely disappeared over a short time period, emphasizing the need for ongoing surveillance and the potential benefit of vaccines that are protective across serogroups.